Clinical trials: Preclinical Alzheimer's Disease
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease, Positron Emission Tomography
Establishment of the Chinese Preclinical Alzheimer's Disease Study With Multiple Neuroimaging
The goal of this observational study is to investigate neuroimage and biomarkers in the Alzheimer's continuum in Chinese population.
- Trial name
- NCT06827678
- Testing
- No Intervention: Observational Cohort
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Huashan Hospital
Alzheimer Disease
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
The purpose of this study is to assess whether JNJ-64042056 affects the spread and build up of tau (a protein in brain) when compared with placebo, using brain scan (tau PET) to determine results from specific areas of the brain.
- Trial name
- Reτain (NCT06544616)
- Testing
- JNJ-64042056
- Where
- 90 sites in United States, Australia and 7 more
- Volunteers
- 55 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Alzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Trial name
- ANCHOR-AD (NCT07142954)
- Testing
- P-tau217 Test
- Where
- 4 sites in United States, Japan
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Preclinical Alzheimer's Disease
AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)
This is a Phase 1, multicenter, randomized, double-blind, placebo-controlled, multiple-dose-escalation study evaluating the safety, tolerability, and immunogenicity of AV-1980R, an investigational vaccine targeting pathological…
- Trial name
- TAURUS-1980 (NCT07158905)
- Testing
- AV-1980R 20 µg, AV-1980R 60 µg, AV-1980R 180 µg
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Institute for Molecular Medicine
Preclinical Alzheimer's Disease, Alzheimer Disease
Alzheimer's Tau Platform: Master Protocol
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late…
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Trial name
- ATP (NCT06957418)
- Testing
- AADvac1, Tau2
- Where
- 7 sites in United States
- Volunteers
- 900 people
- Sponsor
- Paul S. Aisen
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes)
Prediction of Amyloid and Mild Cognitive Impairment in Early Stage Alzheimer's Disease From Remote Speech Phenotyping
The S22 study investigates, in a cross-sectional study, the ability of algorithms that analyse acoustic and linguistic patterns of spoken language to predict the presence of amyloid positivity in early stage Alzheimer's disease…
- Conditions
- Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
- Trial name
- EARS (NCT04928690)
- Volunteers
- 140 people
- Sponsor
- Novoic Limited
Alzheimer Disease, Functional Food
Non-pharmacological Intervention for Preclinical Alzheimer's Disease
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders leading to dementia. Currently, there has been no effective drugs targeting this disease.
- Conditions
- Alzheimer Disease, Functional Food, Subjective Cognitive Decline, Intervention
- Trial name
- NCT04279418
- Testing
- Mixed functional foods supplementation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- XuanwuH 2
Alzheimer Disease, Mild Cognitive Impairment
The Swedish BioFINDER - Preclinical AD Study
This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT06121544
- Testing
- Plasma tau, Plasma β-Amyloid 42/40 (Aβ42/Aβ40), Flutemetamol F18 Injection
- Where
- Sweden
- Volunteers
- 800 people
- Sponsor
- Skane University Hospital
Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease
TMS for Cognitive Decline in Aging and Preclinical AD
In this research study we want to learn more about the effects of non-invasive brain stimulation on motivation, memory, and brain-network function in cognitively unimpaired older adults and individuals with preclinical…
- Conditions
- Prodromal Alzheimer's Disease, Preclinical Alzheimer's Disease, Healthy Aging, Cognitive Decline
- Trial name
- NCT06956300
- Testing
- Active rTMS
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer Disease
The Gut - PRO Study
The purpose of this study is to assess the safety and feasibility of an oral probiotic supplement (PS) intervention in individuals with dementia or mild-cognitive impairment (MCI) due to Alzheimer's disease or at risk of dementia…
- Trial name
- NCT07413744
- Testing
- Probiotic
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer Disease
Imaging Biomarkers in Preclinical and Symptomatic AD
The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD.
- Trial name
- ACS_PIB_IND (NCT04134923)
- Testing
- [11C] Pittsburgh Compound-B (PIB)
- Where
- United States
- Volunteers
- 375 people
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Alzheimer Disease, Dementia
TAS Test: Online Motor-cognitive Tests for Early Detection of Alzheimer's Disease
Global dementia prevalence is rising. Alzheimer's disease (AD), the most common cause, has devastating effects on people's quality of life.
- Conditions
- Alzheimer Disease, Dementia, Age-related Cognitive Decline
- Trial name
- TASTest (NCT05194787)
- Testing
- Cognitive test scores, clinical diagnosis and blood biomarkers
- Where
- Australia
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Tasmania
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Alzheimer's Plasma Extension
The goal of this observational study is to learn how Alzheimer's disease-related blood biomarkers, brain amyloid, and memory and thinking abilities change over time.
- Trial name
- APEX (NCT06416072)
- Testing
- NAV4694
- Where
- 56 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
TRC-PAD Program: In-Clinic Trial-Ready Cohort
The purpose of the TRC-PAD study is to develop a large, well-characterized, biomarker-confirmed, trial-ready cohort to facilitate rapid enrollment into AD prevention trials utilizing the APT Webstudy and subsequent referral to…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease, Dementia
- Trial name
- TRC-PAD (NCT04004767)
- Where
- 45 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Alzheimer Disease, Alzheimer Disease, Early Onset
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood…
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss
- Trial name
- NCT04733989
- Testing
- Biomarker Data Collection
- Where
- 16 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- GAP Innovations, PBC
Preclinical Alzheimer's Disease, Alzheimer Disease
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease.
- Trial name
- AREVIA (NCT07827768)
- Testing
- AV-1959R
- Volunteers
- 160 people
- Sponsor
- Institute for Molecular Medicine
Dementia of the Alzheimer Type, Age-related Cognitive Decline
Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration
DEPEND is an open-label but dosage-masked trial of the retired cholesterol-lowering drug probucol as an agent to increase availability of apolipoprotein E (apoE) in the cerebrospinal fluid (CSF) of cognitively intact older…
- Conditions
- Dementia of the Alzheimer Type, Age-related Cognitive Decline, Mild Cognitive Impairment Due to Alzheimer Disease
- Trial name
- DEPEND (NCT02707458)
- Testing
- Probucol
- Where
- Canada
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Douglas Mental Health University Institute
Alzheimer Disease
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
This substudy will evaluate the effect of crenezumab on the longitudinal tau burden in a subgroup of preclinical Presenilin1 (PSEN1) E280A mutation carriers and non-carriers, who were enrolled in study NCT01998841 (GN28352).
- Trial name
- NCT03977584
- Testing
- Crenezumab, [^18F]GTP1
- Where
- Colombia
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease
PET Changes in Alzheimer's Disease (AD)
The purpose of this study is to identify the earliest predictors of memory and brain deterioration in pre-clinical Alzheimer's disease using positron emission tomography (PET) to monitor brain glucose metabolism.
- Trial name
- NCT00094913
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)